Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC filed a prospectus supplement to its Form F-1 resale registration and incorporated a new Form 6-K. The update highlights European regulatory progress for its lead program.
The company announced EMA approval of a Clinical Trial Application for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis. The CTA permits sites in Denmark, Germany, the Netherlands, and Spain, with Italy expected to be added. The U.S. arm enrolled its first patient in mid-August 2025, and the first European patient is expected in 4Q 2025. The Serenta study is a randomized, double-blind, placebo-controlled registrational trial targeting 168 patients, randomized 2:1 to drug versus placebo. Management cited a $7 billion combined U.S.–Europe addressable market for FAP.
Biodexa’s ADS trade on Nasdaq under BDRX; the last reported closing price on October 31, 2025 was $6.49.
Biodexa Pharmaceuticals (BDRX) reported EMA approval of its Clinical Trial Application, allowing its pivotal Phase 3 Serenta clinical trial of eRapa in patients with familial adenomatous polyposis (FAP) to proceed in Europe.
The CTA covers trial sites in Denmark, Germany, the Netherlands and Spain, with Italy expected to be added. The company also furnished a press release as Exhibit 99.1.
The information under this CTA approval heading is incorporated by reference into the company’s registration statements on Form S-8 (No. 333-209365) and Form F-3 (No. 333-290554), as stated.
Biodexa Pharmaceuticals announced on August 18, 2025 that the first two patients were enrolled in its pivotal Phase 3 Serenta trial of eRapa for familial adenomatous polyposis (FAP) by the Pan American Center for Oncology Trials in San Juan, Puerto Rico. The notice states this enrollment information is incorporated by reference into the company's Form S-8 and Form F-3 registration statements. The company also furnished a press release dated August 18, 2025 as Exhibit 99.1 to the Form 6-K; that exhibit is being furnished and not filed for Exchange Act liability purposes.
Biodexa Pharmaceuticals (NASDAQ: BDRX) has filed a Prospectus Supplement No. 5 to incorporate information from their Form 6-K dated June 27, 2025. The filing covers the resale of 2,486,190,000 ordinary shares (representing 248,619 American Depositary Shares) by selling shareholders.
Key highlights:
- All resolutions at the Annual General Meeting held on June 26, 2025, were successfully passed
- Last reported closing price of ADSs was $0.9215 on NASDAQ Capital Market
- Company's pipeline includes three main development programs: - eRapa: For Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer - Tolimidone: For type 1 diabetes treatment - MTX110: For aggressive rare/orphan brain cancer indications
The company leverages three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of medicines, with headquarters and R&D facility in Cardiff, UK.
Biodexa Pharmaceuticals has filed a prospectus supplement related to the potential resale of 341,352,000,000 ordinary shares (representing 34,135,200 American Depositary Shares). The company's ADSs trade on NASDAQ under symbol BDRX, with a last reported closing price of $0.9215 on June 26, 2025.
The filing also includes Form 6-K reporting the results of their Annual General Meeting held on June 26, 2025, where all proposed resolutions were passed. The company is advancing several key drug development programs:
- eRapa - An oral rapamycin formulation for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer
- Tolimidone - A Lyn kinase inhibitor for type 1 diabetes treatment
- MTX110 - A panobinostat formulation for rare/orphan brain cancers
The company leverages three proprietary drug delivery technologies to improve bio-delivery and bio-distribution of medicines. Their R&D facility is located in Cardiff, UK.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) filed a Form 6-K to report the outcome of its 26 June 2025 Annual General Meeting. The company confirms that every resolution listed in the 23 May 2025 AGM notice was duly approved by shareholders. Although the filing does not enumerate the resolutions or voting percentages, management notes that the results have been incorporated by reference into its effective registration statements on Form S-8 (No. 333-209365) and Form F-3 (No. 333-267932), thereby keeping those shelf offerings current.
A related press release dated 27 June 2025 (Exhibit 99.1) reiterates the successful passage of all motions. The press release is furnished—not filed—under the Exchange Act, limiting potential liability under Section 18.
No financial statements, earnings data, or strategic transaction details were included. The disclosure is largely procedural, aimed at satisfying SEC requirements and informing investors that corporate authorisations—potentially covering director re-elections, auditor appointment, remuneration, and share-issuance mandates—remain in force.